Notably, one more study by Grandal et al. found that less than 20% of pretreated residual triple-negative breast cancer (TNBC) cases exhibited PD-L1 positivity, which is less than the reported in the literature rates for PD-L1 positivity among TNBC [44,45]. The gene discussed is CD274; the disease is triple-negative breast carcinoma.